Free Submission Public Relations & NewsPR-inside.com
Home
Deutsch English

Health

Market Report, "Epzicom (HIV) - Forecast and Market Analysis to 2022", published


Print article Print article
2013-04-05 01:59:44 - New Pharmaceuticals research report from GlobalData is now available from Fast Market Research

GlobalData has released its new PharmaPoint Drug Evaluation report, "Epzicom (HIV) - Forecast and Market Analysis to 2022". Human Immunodeficiency Virus (HIV), the causative agent of AIDS, has claimed millions of lives since its emergence. However, the advent of antiretroviral therapy (ART) has transformed the face of HIV/AIDS from a deadly disease to a manageable chronic condition for most infected individuals. Antiretroviral treatment not only reduces the viral load and reconstitutes immune function, but also decreases infection incidence rates by limiting viral transmission. The treatment algorithm in HIV has characteristically involved multiple drug regimens designed to tackle the virus on different levels. In the recent past, simplified dosing regimens through the emergence of single tablet regimens (STRs) or fixed dose

combination (FDC) therapies have become increasingly popular amongst physicians and patients alike by increasing clinical efficacy thresholds and enabling patient compliance.


Full Report Details at
- www.fastmr.com/prod/555252_epzicom_hiv_forecast_and_market_analy ..


ViiV's Epzicom is a fixed-dose combination of two NRTIs, Ziagen (abacavir sulfate/ABC) and Epivir (lamivudine/3TC). The drug is indicated in combination with other antiretrovirals for the treatment of HIV infection for adults, and for adults and adolescents over the age of 12 years, in the US and EU, respectively (Epzicom Summary of Prescribing Information, 2012; Kivexa Summary of Product Characteristics, 2012).

Scope

* Overview of HIV, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
* Detailed information on Epzicom including product description, safety and efficacy profiles as well as a SWOT analysis.
* Sales forecast for Epzicom for the top nine countries from 2012 to 2022.
* Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, Brazil and China

Reasons to buy

* Understand and capitalize by identifying products that are most likely to ensure a robust return
* Stay ahead of the competition by understanding the changing competitive landscape for HIV
* Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
* Make more informed business decisions from insightful and in-depth analysis of Epzicom performance
* Obtain sales forecast for Epzicom from 2012-2022 in top nine countries (the US, France, Germany, Italy, Spain, the UK, Japan, Brazil and China)

Report Table of Contents:

1 Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Catalyst
2.2 Related Reports
3 Disease Overview
3.1 Etiology and Pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
3.1.3 Prognosis
3.1.4 Quality of Life
3.2 Symptoms
3.2.1 Primary or Acute Infection
3.2.2 Chronic Infection
3.2.3 Advanced Infection/AIDS
4 Disease Management
4.1 Treatment Overview
5 Competitive Assessment
5.1 Overview
5.2 Strategic Competitor Assessment
6 Epzicom (abacavir/lamivudine)
6.1 Overview
6.2 Efficacy
6.3 Safety
6.4 SWOT Analysis
6.5 Forecast
7 Appendix
7.1 Bibliography
7.2 Abbreviations
7.3 Methodology
7.4 Forecasting Methodology
7.4.1 HIV Prevalence
7.4.2 Percent Drug-Treated Patients
7.4.3 General Pricing Assumptions
7.4.4 Individual Drug Assumptions
7.4.5 Generic Erosion
7.5 Physicians and Specialists Included in this Study
7.5.1 Survery of Prescribing Physicians
7.6 About the Authors
7.6.1 Authors
7.6.2 Global Head of Healthcare
7.7 About GlobalData
7.8 Contact Us
7.9 Disclaimer

List of Tables

1.1 List of Tables
Table 1: Symptoms HIV
Table 2: Treatment Guidelines for HIV
Table 3: Most Prescribed Drugs for HIV by Class in the Global Markets, 2012
Table 4: Leading Treatments for HIV, 2012
Table 5: Product Profile - Epzicom
Table 6: Epzicom SWOT Analysis, 2012
Table 7: Global Sales Forecasts ($m) for Epzicom, 2012-2022
Table 8: Physicians Surveyed, By Country

List of Figures

1.2 List of Figures
Figure 1: HIV Lifecycle

About GlobalData

GlobalData is a leading provider of global business intelligence including market, competitor, product and customer information. It provides in-depth research, analysis, data and forecasts through a range of interactive online databases, reports and management briefings. GlobalData has a large team of experienced research and analysis, consulting, and marketing experts. It has a global presence, including key offices in the US, Europe and Asia. The group has over 50 years of experience of delivering market intelligence data and analysis and a highly experienced senior management team. View more research from GlobalData at www.fastmr.com/catalog/publishers.aspx?pubid=1015

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156.


Author:
Bill Thompson
e-mail
Web: www.fastmr.com
Phone: 18008448156

Disclaimer: If you have any questions regarding information in these press releases please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims contents contained in this release.
Latest News
Read the Latest News
www.newsenvoy.com

 


Terms & Conditions | Privacy | About us | Contact PR-inside.com